ea0090p750 | Thyroid | ECE2023
Katz Barrett
, Turbin Roger
, Cockerham Kimberly
, Tang Rosa
, Nijhawan Navdeep
, Ugradar Shoaib
, O'Shaughnessy Denis J.
, Summerfelt Rochelle M.
, She Angela
, Douglas Raymond
Purpose: IGF-1R antagonism reduces TED-related inflammation and proptosis. VRDN-001, a subnanomolar affinity full antagonist antibody to IGF-1R, is being evaluated in a phase 1/2 RCT (NCT05176639) at 3-20 mg/kg. We present results from the first cohort (10 mg/kg) of TED patients.Methods: Adults with active moderate-to-severe TED with clinical activity score (CAS) ≥4 were randomized to 2 infusions 3 weeks apart of either 10 mg/kg VRDN-001 or placebo...